Henry Schein, Inc. $HSIC Shares Sold by Amundi

Key Points

• Amundi significantly reduced its stake in Henry Schein, Inc. by 86.8%, selling 639,405 shares and maintaining only 97,232 shares valued at approximately $6.5 million.
• Several institutional investors, including JPMorgan Chase & Co. and Burgundy Asset Management Ltd., increased their holdings in Henry Schein during the same quarter, reflecting varied investor sentiment.
• Henry Schein recently reported earnings per share of $1.10 for the quarter, which missed analyst expectations, while also providing fiscal year guidance of 4.800-4.940 EPS for FY 2025.

Amundi reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 86.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,232 shares of the company's stock after selling 639,405 shares during the period. Amundi owned 0.08% of Henry Schein worth $6,475,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC raised its stake in Henry Schein by 18.2% during the fourth quarter. Jane Street Group LLC now owns 25,556 shares of the company's stock worth $1,768,000 after purchasing an additional 3,932 shares during the period. Baird Financial Group Inc. increased its holdings in shares of Henry Schein by 36.3% during the 4th quarter. Baird Financial Group Inc. now owns 5,438 shares of the company's stock worth $376,000 after buying an additional 1,447 shares during the last quarter. Deutsche Bank AG raised its position in shares of Henry Schein by 21.0% in the 4th quarter. Deutsche Bank AG now owns 647,022 shares of the company's stock worth $44,774,000 after buying an additional 112,408 shares during the period. Ethic Inc. boosted its holdings in Henry Schein by 13.1% in the fourth quarter. Ethic Inc. now owns 13,423 shares of the company's stock valued at $929,000 after acquiring an additional 1,552 shares during the last quarter. Finally, Graham Capital Management L.P. purchased a new stake in Henry Schein during the fourth quarter valued at about $1,015,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Down 0.6%

Shares of HSIC stock traded down $0.42 on Tuesday, hitting $68.39. The stock had a trading volume of 1,258,087 shares, compared to its average volume of 1,416,795. The stock's 50 day moving average is $69.12 and its 200-day moving average is $69.41. The firm has a market capitalization of $8.29 billion, a price-to-earnings ratio of 22.06, a P/E/G ratio of 2.27 and a beta of 0.86. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.22 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The business's quarterly revenue was up 3.3% on a year-over-year basis. During the same period last year, the firm earned $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on Henry Schein from $80.00 to $76.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Evercore ISI upgraded shares of Henry Schein from an "in-line" rating to an "outperform" rating and set a $83.00 price target on the stock in a report on Tuesday, August 26th. Baird R W downgraded shares of Henry Schein from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Leerink Partners set a $75.00 price objective on shares of Henry Schein in a research report on Monday, July 14th. Finally, Wall Street Zen lowered shares of Henry Schein from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $76.67.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.